

Boehringer Ingelheim India focuses on partnerships in NCD management

25 March 2021 | News

Company to sustain growth momentum in 2021

Boehringer Ingelheim India has shared its roadmap of partnerships and patient access programmes to sustain its growth momentum in 2021.

Vani Manja, Managing Director, Boehringer Ingelheim India said, "Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction."

In diabetes, Boehringer Ingelheim's research and development has been focused on bringing comprehensive solutions to the management of Type 2 diabetes and its related cardio-renal-metabolic complications. The Company has been investing significantly in understanding the condition in its entirety.

In the area of stroke, Boehringer Ingelheim India has established a partnership model to help hospitals across 23 States and 3 UTs to improve the standard of care for stroke management. The partnership model entails – 1. development of an increased network of stroke-ready centres across India; 2. supporting healthcare professionals with world-class training to identify and treat stroke within the recommended treatment window; and 3. enabling an ecosystem for stroke care by bringing in multi-disciplinary teams that can address disease management through the continuum of care.

Boehringer Ingelheim India collaborates with 380 centers enabling support for over 10,000 patients to access effective stroke care.

In addition to Human Pharma, Boehringer Ingelheim India's Animal Health business, which focuses on advanced, preventive health solutions for Pets and Poultry, aims to more than double the sales over the coming five years.